ArticleEpilepsia open2025
Effects of perampanel on bone health in adult patients with epilepsy.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Correlation between thyroid hormone levels and cognitive dysfunction in older patients with subclinical hypothyroidism : A matched groups retrospective study.Wiener klinische Wochenschrift · 2026Article
- MonoPER study: Effectiveness and tolerability of PERampanel in monotherapy in real-world after 12 months of treatment.Epilepsia open · 2025Observational
- Effects of perampanel on bone health in adult patients with epilepsy.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe objective was to assess the effects of perampanel (PER) on bone metabolism and bone mineral density (BMD) in adult patients with epilepsy.
methodsThis retrospective study included consecutive patients admitted to the Epilepsy Center of Sichuan Provincial People's Hospital from January 2023 to June 2024. A total of 39 patients who completed bone metabolism and BMD evaluations after 1 year of PER treatment were included in the PER group. The control group comprised 44 patients with newly diagnosed epilepsy. A cross-sectional analysis was conducted between the two groups. We conducted a subgroup analysis of patients stratified by seizure frequency and type. Patients in the PER group were further stratified according to their seizure frequency and seizure type. Finally, we performed a cohort study involving 10 PER-treated patients whose baseline data were available prior to initiating PER therapy.
resultsNo significant differences in bone mineral density were observed between the experimental groups and the control group. With respect to bone metabolism, minor alterations were observed only in thyroid hormone levels and serum magnesium concentrations relative to those of the controls. No significant differences in bone metabolism or BMD were observed before or after PER treatment. SIGNIFICANCE: Short-term PER treatment did not significantly affect bone mineral density in adult patients with epilepsy. PLAIN LANGUAGE SUMMARY: This study investigated how PER, a drug used to treat epilepsy, affects bone health in adult patients. Researchers compared 39 patients who were treated with PER for 1 year with 44 patients with newly diagnosed epilepsy. They did not observe significant differences in BMD between the two groups. Some minor changes were observed in thyroid hormone and magnesium levels in the blood, but overall, PER treatment did not have a major effect on bone metabolism or BMD. This study suggested that the short-term use of PER does not significantly affect bone health in people with epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.